美国媒体周四报道，在芝加哥大学的一项临床研究中，接受瑞德西韦的125名COVID-19晚期患者在治疗一周后，差不多全部出院，仅有2例死亡。吉利德股票盘后暴涨13%
Late Thursday, health-care media site Stat (https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/) reported that nearly all 125 COVID-19 patients in a late-stage clinical study at the University of Chicago treated with Gilead's remdesivir had been discharged after a week of treatment. Stat reported that 113 patients had a severe form of the disease and that two had died. The University of Chicago results, however, are only part of a larger study group that includes 2,400 patients with a severe form of COVID-19 and 1,600 ones with a moderate form. Gilead expects to start releasing results in April. Last week, an analysis published in the New England Journal of Medicine (http://www.marketwatch.com/story/gileads-drug-shows-some-efficacy-among-small-group-of-covid-19-patients-2020-04-10) claimed most COVID-19 patients given remdesivir showed clinical improvement.
閱讀更多 VIAGENE經理 的文章
